Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Brooke A. Jennings"'
Autor:
Matthew W. Stefan, David M. Gundermann, Matthew H. Sharp, Brooke A. Jennings, Raad H. Gheith, Ryan P. Lowery, Tieraona LowDog, Somsuvra B. Ghatak, Jose Barbosa, Jacob M. Wilson
Publikováno v:
Nutrients, Vol 15, Iss 11, p 2620 (2023)
(1) Background: Iron deficiency without anemia (IDWA) is a prevalent health concern in premenopausal women. Oral supplementation of iron may be a viable solution to improve blood-iron status in women; however, the effects of a high-dose iron-suppleme
Externí odkaz:
https://doaj.org/article/f52b3282cde44f0aa47923929177f45c
Autor:
Wilson, Matthew W. Stefan, David M. Gundermann, Matthew H. Sharp, Brooke A. Jennings, Raad H. Gheith, Ryan P. Lowery, Tieraona LowDog, Somsuvra B. Ghatak, Jose Barbosa, Jacob M.
Publikováno v:
Nutrients; Volume 15; Issue 11; Pages: 2620
(1) Background: Iron deficiency without anemia (IDWA) is a prevalent health concern in premenopausal women. Oral supplementation of iron may be a viable solution to improve blood-iron status in women; however, the effects of a high-dose iron-suppleme
Autor:
Adam J. Dupuy, Christopher S. Stipp, Jesse D. Riordan, Jeremy Bobera, Sarah A. Mullen, Brooke M. Jennings, Eliot Y. Zhu, Andrew P. Voigt, Lexy S. Wadsworth, Hayley R. Vaughn, Afshin Varzavand, Jacob L. Schillo, Charlotte R. Feddersen
The use of selective BRAF inhibitors (BRAFi) has produced remarkable outcomes for patients with advanced cutaneous melanoma harboring a BRAFV600E mutation. Unfortunately, the majority of patients eventually develop drug-resistant disease. We employed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eaeb0dd15610b75d4835c5c2b200b47
https://doi.org/10.1158/0008-5472.c.6510806
https://doi.org/10.1158/0008-5472.c.6510806
Autor:
Adam J. Dupuy, Christopher S. Stipp, Jesse D. Riordan, Jeremy Bobera, Sarah A. Mullen, Brooke M. Jennings, Eliot Y. Zhu, Andrew P. Voigt, Lexy S. Wadsworth, Hayley R. Vaughn, Afshin Varzavand, Jacob L. Schillo, Charlotte R. Feddersen
Supplemental figures showing more detailed analysis of the genetic screen results (S1-S3), additional experiments showing biological validation of major candidate genes (S4-S7), and characterization of spontaneous Vemurafenib resistance in A375 cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::763c2810c62639764eae9b5898ddc732
https://doi.org/10.1158/0008-5472.22420994
https://doi.org/10.1158/0008-5472.22420994
Autor:
Adam J. Dupuy, Christopher S. Stipp, Jesse D. Riordan, Jeremy Bobera, Sarah A. Mullen, Brooke M. Jennings, Eliot Y. Zhu, Andrew P. Voigt, Lexy S. Wadsworth, Hayley R. Vaughn, Afshin Varzavand, Jacob L. Schillo, Charlotte R. Feddersen
This file contains 4 supplemental tables.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bb40e1219583d6c2b577a68cb4a9de0
https://doi.org/10.1158/0008-5472.22420997.v1
https://doi.org/10.1158/0008-5472.22420997.v1
Autor:
Jeremy Bobera, Charlotte R. Feddersen, Sarah A. Mullen, Jesse D. Riordan, Lexy S. Wadsworth, Jacob L. Schillo, Adam J. Dupuy, Hayley R. Vaughn, Christopher S. Stipp, Brooke M. Jennings, Andrew P. Voigt, Afshin Varzavand, Eliot Y. Zhu
Publikováno v:
Cancer Research. 79:5074-5087
The use of selective BRAF inhibitors (BRAFi) has produced remarkable outcomes for patients with advanced cutaneous melanoma harboring a BRAFV600E mutation. Unfortunately, the majority of patients eventually develop drug-resistant disease. We employed